BACKGROUND: An ascending aortic aneurysm (AscAA) is a silent, potentially fatal condition, as it increases the risk of aortic wall failure through dissection or rupture. With an increasing prevalence, aortic disease now occupies the position of the 19th leading cause of death in the United States. Surgical intervention is indicated when the diameter exceeds 55 mm, or at smaller diameters in the presence of comorbidities or high-risk clinical features. While elective surgical treatment is prophylactic, many who present with catastrophic acute aortic failure do so at diameters below these surgical criteria. As current guideline thresholds rely primarily on aortic diameter, these strategies remain blind to the underlying aortic biology that determines rates of disease progression. Furthermore, there is currently no targeted medical treatment.AscAA encompasses multiple aetiologies with the same clinical manifestation - a dilatation of the ascending aortic segment. Discernible aetiologies, including syndromic disease and familial thoracic aortopathies, are increasingly found in clinical practice but are at the present time expected to make up 20-23% of surgical cohorts. The two most prevalent forms of AscAA are the degenerative AscAA, and the form manifesting in patients with a bicuspid aortic valve (BAV) - the most common (about 0.5-1.4% of the general population) congenital malformation of the heart valves. While the mechanisms of disease for these two forms are not fully known, multiple lines of evidence suggest different molecular and histopathological phenotypes.AIMS: This thesis aims to develop new insights into AscAA pathogenesis from molecular, cellular, and translational perspectives, with a focus on degenerative and BAV-associated forms. Specifically, the thesis aims to characterise endothelial-to-mesenchymal transition (EndMT) in degenerative and BAV-associated aortopathy. Additional aims include identification of drivers of fibrotic and inflammatory remodelling, investigation of mechanisms linking aortic valve disease to early aortic wall pathology, and evaluation of whether transcriptomic subtypes of ascending aortic tissue inform post-operative clinical heterogeneity.MATERIALS AND METHODS: Across all studies, investigations were primarily conducted in two cohorts of patients undergoing open heart surgery for either ascending aortic surgery, aortic valve replacement or both at the Karolinska University Hospital in Solna, Sweden. For the first cohort, operated between 2007 and 2013, patients were recontacted to inquire about participation in a 10-year radiological follow-up. For the majority of patients in this cohort, retrospective information on death and aortic events was collected through the medical records. The second cohort was started in 2012 and is still ongoing. In both cohorts, biological samples were collected from dilated and non-dilated ascending aortas, as well as plasma and whole blood. Human aortic tissue was used for transcriptomic exon arrays, spatial transcriptomics, proteomics, and primary cell isolation. In-house data on physiological rat aortic expression was used, and external single-cell matrices were produced from cohorts in Munich, Germany for cellular deconvolution.RESULTS: In study I we found that EndMT processes specific to BAV-associated AscAA had similar characteristics to embryonic EndMT, and we found a loss of canonical endothelial function in BAV-associated aortas even in the absence of dilatation, as evidenced by loss of CD31, decreased endothelial laminin y1, and subintimal accumulation of albumin as a proxy for endothelial permeability. In study II, the EndMT process was seemingly driven by osteopontin, in part expressed by CD68-positive cells. The expression of osteopontin may be regulated by distal enhancers affected by the transcription factor ETS1, in the context of inflammatory cells. This regulatory function could further be validated by cellular perturbations and in degenerative AscAA tissue. In study III, following up on the inflammatory phenotype of degenerative AscAA, we observed an association of nascent subintimal oxLDL and endothelial activation in non-dilated aortas of patients with aortic regurgitation, with potential downstream effects exacerbating inflammatory activity by CD68-positive cells. When following a subset of patients having undergone aortic valve replacement, we found that those who were operated for aortic regurgitation did not continue to grow, but patients with aortic stenosis (who rarely develop degenerative AscAA) did grow. Data from the follow-up on patients undergoing aortic valve and/or ascending aortic surgery was then leveraged in study IV to identify context-agnostic transcriptomic subtypes of aortic expression associated with late aortic events. We identified a subset of degenerative AscAA with a particularly inflammatory gene expression profile, which was associated with a significantly higher risk of residual disease through aneurysm development in the remaining ascending aorta. This subtype may be distinguishable from other degenerative AscAA through blood-borne plasma proteins.CONCLUSIONS: This thesis demonstrates that AscAA comprises biologically distinct disease processes linked to aortic valve phenotype. Endothelial dysfunction emerges as an early and central feature in both BAV-associated and degenerative AscAA; however, the underlying disease programs differ. BAV-associated aortopathy is characterised by features consistent with developmental endothelial dysfunction, whereas degenerative AscAA is more closely associated with endothelial activation, inflammation, and fibrotic degeneration. In degenerative AscAA, inflammatory activity may persist beyond the resected aortic segment and be associated with residual post-operative aortic risk. Collectively, these findings suggest that biologically informed approaches may complement current diameter-based guidelines in the future management of...